Holen Sie sich die Stockscreener-App
138.60
2.71%
3.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$134.94
Offen:
$136.16
24-Stunden-Volumen:
1.64M
Relative Volume:
1.14
Marktkapitalisierung:
$20.32B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
13.68
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+6.07%
1M Leistung:
+8.71%
6M Leistung:
+0.92%
1J Leistung:
-31.26%
1-Tages-Spanne:
$135.88
$138.83
1-Wochen-Bereich:
$127.71
$138.83
52-Wochen-Spanne:
$110.03
$207.59
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
138.60 | 19.78B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
701.23 | 613.56B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.64 | 420.78B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.69 | 361.58B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.21 | 236.35B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.21 | 206.72B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Stock Analysis | Biogen OutlookA Mixed Picture With Technical Caution and Strong Analyst Optimism - AInvest
Inspire Trust Co. N.A. Purchases 2,000 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - MSN
Resona Asset Management Co. Ltd. Buys 2,104 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Forecasts Biogen's Q4 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Trimmed by Entropy Technologies LP - MarketBeat
Mizuho Securities USA LLC Sells 2,091 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Forsta AP Fonden - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by LPL Financial LLC - MarketBeat
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Biogen’s New Clinical Trial: A Potential Game-Changer for Kidney Transplant Patients - TipRanks
Biogen’s Omaveloxolone Study: A New Hope for Young FA Patients - TipRanks
Biogen’s Litifilimab Study: A Long-Term Look at Lupus Treatment - TipRanks
E Fund Management Co. Ltd. Acquires 3,160 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development - MSN
Deutsche Bank AG Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
National Bank of Canada FI Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
White Lighthouse Investment Management Inc. Purchases New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Raised by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
April 2026 Options Now Available For Biogen (BIIB) - Nasdaq
Piper Sandler raises Biogen stock price target to $118 on Alzheimer’s drug data By Investing.com - Investing.com South Africa
AIA Group Ltd Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Dementia and Alzheimer's Disease Treatment Market To Witness - openPR.com
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Aigen Investment Management LP Invests $1.97 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Rate Cut Rationale and Healthcare Gains: Evaluating the Surge in Biogen, Moderna, and Align Tech - AInvest
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of ... - Bluefield Daily Telegraph
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know - TradingView
Why Is Biogen Stock Climbing Wednesday?Biogen (NASDAQ:BIIB) - Benzinga
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments - TipRanks
Rituxan Market Size to 2025: Emerging Demands, Trends, - openPR.com
Biogen Asserts No Obligation to Pay $122M in Intellectual Property Royalties Following Mistrial - USA Herald
5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call - Yahoo Finance
BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Motley Fool Asset Management LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Invesco Ltd. - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ontario Teachers Pension Plan Board Buys Shares of 10,849 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Says It Owes Nothing After $122M IP Royalties Mistrial - Law360
Sector Update: Health Care - MarketScreener
Biogen CEO Sees Potential in Combining Alzheimer's, Obesity Drugs - MarketScreener
Biogen CEO sees potential in combining Alzheimer's and obesity drugs, despite Novo's trial success. - AInvest
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment? - TipRanks
Biogen Sees Potential in Combining Alzheimer’s and Obesity Drugs - Bloomberg.com
Headlands Technologies LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment - TipRanks
Biogen Faces Growing Pains Even As Its Pipeline Progresses - Finimize
Stoke Therapeutics, Biogen Announce First Patient Dosed in EMPEROR Study for Dravet Syndrome Treatment - AInvest
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):